Novel prime-boost vaccine strategies against HIV-1

References

• UNAIDS. Miles to go. Switzerland: Geneva; 2018.
   Google Scholar
• UNAIDS data. Switzerland: Geneva; 2018.
   Google Scholar
• Fauci AS. An HIV vaccine is essential for ending the HIV/AIDS pandemic. JAMA. 2017;318(16):1535–1536.
   PubMed Web of Science ®Google Scholar
• Eisinger RW, Fauci AS. Ending the HIV/AIDS pandemic. Emerg Infect Dis. 2018;24(3):413–416.
   PubMed Web of Science ®Google Scholar
• Institute for Health Metrics and Evaluation. Financing Global Health. Funding universal health coverage and the unfinished HIV/AIDS agenda. Seattle WA, USA: University of Washington; 2017.
   Google Scholar
• UNAIDS. Fact sheet – World AIDS Day 2018.
   Google Scholar
• Harmon TM, Fisher KA, McGlynn MG, et al. Exploring the potential health impact and cost-effectiveness of AIDS vaccine within a comprehensive HIV/AIDS response in low- and middle-income countries. PLoS One. 2016;11(1):e0146387.
   PubMed Web of Science ®Google Scholar
• Dimitrov D, Kublin JG, Ramsey S, et al. Are clade specific HIV vaccines a necessity? An analysis based on mathematical models. EBioMedicine. 2015;2(12):2062–2069.
   PubMed Web of Science ®Google Scholar
• de Montigny S, Adamson BJS, Masse BR, et al. Projected effectiveness and added value of HIV vaccination campaigns in South Africa: a modeling study. Sci Rep. 2018;8(1):6066.
   PubMedGoogle Scholar
• Hsu DC, O’Connell RJ. Progress in HIV vaccine development. Hum Vaccin Immunother. 2017;13(5):1018–1030.
   PubMed Web of Science ®Google Scholar
• Stephenson KE, D’Couto HT, Barouch DH. New concepts in HIV-1 vaccine development. Curr Opin Immunol. 2016;41:39–46.
   PubMed Web of Science ®Google Scholar
• Alayo QA, Provine NM, Penaloza-MacMaster P. Novel concepts for HIV vaccine vector design. mSphere. 2017;2(6):e00415–e17.
   PubMedGoogle Scholar
• Excler JL, Robb ML, Kim JH. HIV-1 vaccines: challenges and new perspectives. Hum Vaccin Immunother. 2014;10(6):1734–1746.
   PubMed Web of Science ®Google Scholar
• Excler JL, Robb ML, Kim JH. Prospects for a globally effective HIV-1 vaccine. Vaccine. 2015;33(Suppl 4):D4–D12.
   PubMedGoogle Scholar
• Excler JL, Tomaras GD, Russell ND. Novel directions in HIV-1 vaccines revealed from clinical trials. Curr Opin HIV AIDS. 2013;8(5):421–431.
   PubMed Web of Science ®Google Scholar
• Gao Y, McKay PF, Mann JFS. Advances in HIV-1 vaccine development. Viruses. 2018;10(4):167.
   PubMed Web of Science ®Google Scholar
• Kardani K, Bolhassani A, Shahbazi S. Prime-boost vaccine strategy against viral infections: mechanisms and benefits. Vaccine. 2016;34(4):413–423.
   PubMed Web of Science ®Google Scholar
• Lu S. Heterologous prime-boost vaccination. Curr Opin Immunol. 2009;21(3):346–351.
   PubMed Web of Science ®Google Scholar
• Ramshaw IA, Ramsay AJ. The prime-boost strategy: exciting prospects for improved vaccination. Immunol Today. 2000;21(4):163–165.
   PubMedGoogle Scholar
• Excler JL, Plotkin S. The prime-boost concept applied to HIV preventive vaccines. AIDS. 1997;11(Suppl A):S127–S137.
   PubMedGoogle Scholar
• Plotkin SA. Vaccines: correlates of vaccine-induced immunity. Clin Infect Dis. 2008;47(3):401–409.
   PubMed Web of Science ®Google Scholar
• Streeck H, D’Souza MP, Littman DR, et al. Harnessing CD4(+) T cell responses in HIV vaccine development. Nat Med. 2013;19(2):143–149.
   PubMed Web of Science ®Google Scholar
• Havenar-Daughton C, Carnathan DG, Torrents de la Pena A, et al. Direct probing of germinal center responses reveals immunological features and bottlenecks for neutralizing antibody responses to HIV env trimer. Cell Rep. 2016;17(9):2195–2209.
   PubMed Web of Science ®Google Scholar
• Khurana S, Coyle EM, Dimitrova M, et al. Heterologous prime-boost vaccination with MF59-adjuvanted H5 vaccines promotes antibody affinity maturation towards the hemagglutinin HA1 domain and broad H5N1 cross-clade neutralization. PLoS One. 2014;9(4):e95496.
   PubMed Web of Science ®Google Scholar
• Gamble LJ, Matthews QL. Current progress in the development of a prophylactic vaccine for HIV-1. Drug Des Devel Ther. 2010;5:9–26.
   PubMed Web of Science ®Google Scholar
• Hemelaar J, Elangovan R, Yun J, et al. Global and regional molecular epidemiology of HIV-1, 1990-2015: a systematic review, global survey, and trend analysis. Lancet Infect Dis. 2019;19(2):143–155.
   PubMed Web of Science ®Google Scholar
• Phanuphak N, Lo YR, Shao Y, et al. HIV epidemic in Asia: implications for HIV vaccine and other prevention trials. AIDS Res Hum Retroviruses. 2015;31(11):1060–1076.
   PubMed Web of Science ®Google Scholar
• McCoy LE. The expanding array of HIV broadly neutralizing antibodies. Retrovirology. 2018;15(1):70.
   PubMed Web of Science ®Google Scholar
• Sok D, Burton DR. Recent progress in broadly neutralizing antibodies to HIV. Nat Immunol. 2018;19(11):1179–1188.
   PubMed Web of Science ®Google Scholar
• Excler JL, Ake J, Robb ML, et al. Nonneutralizing functional antibodies: a new “old” paradigm for HIV vaccines. Clin Vaccine Immunol. 2014;21(8):1023–1036.
   PubMed Web of Science ®Google Scholar
• Barouch DH, O’Brien KL, Simmons NL, et al. Mosaic HIV-1 vaccines expand the breadth and depth of cellular immune responses in rhesus monkeys. Nat Med. 2010;16(3):319–323.
   PubMed Web of Science ®Google Scholar
• Alter G, Barouch D. Immune correlate-guided HIV vaccine design. Cell Host Microbe. 2018;24(1):25–33.
   PubMed Web of Science ®Google Scholar
• Rerks-Ngarm S, Pitisuttithum P, Nitayaphan S, et al. Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N Engl J Med. 2009;361(23):2209–2220.
   PubMed Web of Science ®Google Scholar
• Robb ML, Rerks-Ngarm S, Nitayaphan S, et al. Risk behaviour and time as covariates for efficacy of the HIV vaccine regimen ALVAC-HIV (vCP1521) and AIDSVAX B/E: a post-hoc analysis of the Thai phase 3 efficacy trial RV 144. Lancet Infect Dis. 2012;12(7):531–537.
   PubMed Web of Science ®Google Scholar
• Montefiori DC, Karnasuta C, Huang Y, et al. Magnitude and breadth of the neutralizing antibody response in the RV144 and Vax003 HIV-1 vaccine efficacy trials. J Infect Dis. 2012;206(3):431–441.
   PubMed Web of Science ®Google Scholar
• Rerks-Ngarm S, Paris RM, Chunsutthiwat S, et al. Extended evaluation of the virologic, immunologic, and clinical course of volunteers who acquired HIV-1 infection in a phase III vaccine trial of ALVAC-HIV and AIDSVAX B/E. J Infect Dis. 2013;207(8):1195–1205.
   PubMed Web of Science ®Google Scholar
• Haynes BF, Gilbert PB, McElrath MJ, et al. Immune-correlates analysis of an HIV-1 vaccine efficacy trial. N Engl J Med. 2012;366(14):1275–1286.
   PubMed Web of Science ®Google Scholar
• Vasan S, Rerks-Ngarm S, Gilbert P, et al. Letter to the editor on: the RV144 vaccine regimen was not associated with enhancement of infection. Hum Vaccin Immunother. 2015;11(4):1036–1037.
   PubMed Web of Science ®Google Scholar
• O’Connell RJ, Excler JL. HIV vaccine efficacy and immune correlates of risk. Curr HIV Res. 2013;11(6):450–463.
   PubMed Web of Science ®Google Scholar
• Kim JH, Excler JL, Michael NL. Lessons from the RV144 thai phase III HIV-1 vaccine trial and the search for correlates of protection. Annu Rev Med. 2015;66:423–437.
   PubMed Web of Science ®Google Scholar
• Corey L, Gilbert PB, Tomaras GD, et al. Immune correlates of vaccine protection against HIV-1 acquisition. Sci Transl Med. 2015;7(310):310rv317.
   Web of Science ®Google Scholar
• Tomaras GD, Plotkin SA. Complex immune correlates of protection in HIV-1 vaccine efficacy trials. Immunol Rev. 2017;275(1):245–261.
   PubMed Web of Science ®Google Scholar
• Rolland M, Edlefsen PT, Larsen BB, et al. Increased HIV-1 vaccine efficacy against viruses with genetic signatures in Env V2. Nature. 2012;490(7420):417–420.
   PubMed Web of Science ®Google Scholar
• Zolla-Pazner S, deCamp AC, Cardozo T, et al. Analysis of V2 antibody responses induced in vaccinees in the ALVAC/AIDSVAX HIV-1 vaccine efficacy trial. PLoS One. 2013;8(1):e53629.
   PubMed Web of Science ®Google Scholar
• Zolla-Pazner S, Decamp A, Gilbert PB, et al. Vaccine-induced IgG antibodies to V1V2 regions of multiple HIV-1 subtypes correlate with decreased risk of HIV-1 infection. PLoS One. 2014;9(2):e87572.
   PubMed Web of Science ®Google Scholar
• Liao HX, Bonsignori M, Alam SM, et al. Vaccine induction of antibodies against a structurally heterogeneous site of immune pressure within HIV-1 envelope protein variable Regions 1 and 2. Immunity. 2013;38(1):176–186.
   PubMed Web of Science ®Google Scholar
• Chung AW, Ghebremichael M, Robinson H, et al. Polyfunctional Fc-effector profiles mediated by IgG subclass selection distinguish RV144 and VAX003 vaccines. Sci Transl Med. 2014;6(228):228ra238.
   Web of Science ®Google Scholar
• Tay MZ, Liu P, Williams LD, et al. Antibody-mediated internalization of infectious HIV-1 virions differs among antibody isotypes and subclasses. PLoS Pathog. 2016;12(8):e1005817.
   PubMed Web of Science ®Google Scholar
• Yates NL, Liao HX, Fong Y, et al. Vaccine-induced env V1-V2 IgG3 correlates with lower HIV-1 infection risk and declines soon after vaccination. Sci Transl Med. 2014;6(228):228ra239.
   Web of Science ®Google Scholar
• Perez LG, Martinez DR, deCamp AC, et al. V1V2-specific complement activating serum IgG as a correlate of reduced HIV-1 infection risk in RV144. PLoS One. 2017;12(7):e0180720.
   PubMed Web of Science ®Google Scholar
• Liu P, Yates NL, Shen X, et al. Infectious virion capture by HIV-1 gp120-specific IgG from RV144 vaccinees. J Virol. 2013;87(14):7828–7836.
   PubMed Web of Science ®Google Scholar
• Fahrbach KM, Malykhina O, Stieh DJ, et al. Differential binding of IgG and IgA to mucus of the female reproductive tract. PLoS One. 2013;8(10):e76176.
   PubMed Web of Science ®Google Scholar
• Gunn B, Schneider J, Shansab M, et al. Enhanced binding of antibodies generated during chronic HIV infection to mucus component MUC16. Mucosal Immunol. 2016;9(6):1549–1558.
   PubMed Web of Science ®Google Scholar
• Wines BD, Billings H, McLean MR, et al. Antibody functional assays as measures of Fc receptor-mediated immunity to HIV – new technologies and their impact on the HIV vaccine field. Curr HIV Res. 2017;15(3):202–215.
   PubMed Web of Science ®Google Scholar
• Huang Y, Ferrari G, Alter G, et al. Diversity of antiviral IgG effector activities observed in HIV-infected and vaccinated subjects. J Immunol. 2016;197(12):4603–4612.
   PubMed Web of Science ®Google Scholar
• Tomaras GD, Ferrari G, Shen X, et al. Vaccine-induced plasma IgA specific for the C1 region of the HIV-1 envelope blocks binding and effector function of IgG. Proc Natl Acad Sci U S A. 2013;110(22):9019–9024.
   PubMed Web of Science ®Google Scholar
• Gottardo R, Bailer RT, Korber BT, et al. Plasma IgG to linear epitopes in the V2 and V3 regions of HIV-1 gp120 correlate with a reduced risk of infection in the RV144 vaccine efficacy trial. PLoS One. 2013;8(9):e75665.
   PubMed Web of Science ®Google Scholar
• Zolla-Pazner S, Edlefsen PT, Rolland M, et al. Vaccine-induced human antibodies specific for the third variable region of HIV-1 gp120 impose immune pressure on infecting viruses. EBioMedicine. 2014;1(1):37–45.
   PubMed Web of Science ®Google Scholar
• Lin L, Finak G, Ushey K, et al. COMPASS identifies T-cell subsets correlated with clinical outcomes. Nat Biotechnol. 2015;33(6):610–616.
   PubMed Web of Science ®Google Scholar
• Rerks-Ngarm S, Pitisuttithum P, Excler JL, et al. Randomized, double-blind evaluation of late boost strategies for HIV-uninfected vaccine recipients in the RV144 HIV vaccine efficacy trial. J Infect Dis. 2017;215(8):1255–1263.
   PubMed Web of Science ®Google Scholar
• Akapirat S, Karnasuta C, Vasan S, et al. Characterization of HIV-1 gp120 antibody specificities induced in anogenital secretions of RV144 vaccine recipients after late boost immunizations. PLoS One. 2018;13(4):e0196397.
   PubMed Web of Science ®Google Scholar
• Easterhoff D, Moody MA, Fera D, et al. Boosting of HIV envelope CD4 binding site antibodies with long variable heavy third complementarity determining region in the randomized double blind RV305 HIV-1 vaccine trial. PLoS Pathog. 2017;13(2):e1006182.
   PubMed Web of Science ®Google Scholar
• Shen X, Moodie Z, McMillan A, et al. V1V2 IgG and antibody Fc effector functions in a subtype C ALVAC-HIV and bivalent subtype C gp120/MF59 HIV-1 vaccine trial in South Africa (HIVR4P 2018, abstract OA02.03). AIDS Res Hum Retroviruses. 2018;34(S1):17.
   Google Scholar
• Bekker LG, Moodie Z, Grunenberg N, et al. Subtype C ALVAC-HIV and bivalent subtype C gp120/MF59 HIV-1 vaccine in low-risk, HIV-uninfected, South African adults: a phase 1/2 trial. Lancet HIV. 2018;5(7):e366–e378.
   PubMed Web of Science ®Google Scholar
• Gray GE, Andersen-Nissen E, Grunenberg N, et al. HVTN 097: evaluation of the RV144 vaccine regimen in HIV uninfected South African adults (HIVR4P 2014, abstract). AIDS Res Hum Retroviruses. 2014;30(S1):A33–A34.
   Google Scholar
• Fleming L, Andersen-Nissen E, Fiore-Gartland A, et al. Systems analysis of the innate and adaptive immune responses to the RV144 ALVAC HIV vaccine in a South African HIV uninfected cohort (HIVR4P 2018, abstract P26.03). AIDS Res Hum Retroviruses. 2018;34(S1):378.
   Google Scholar
• Cohen K, Malahleha M, Laher F, et al. Increase in env-specific binding antibody and CD4+ T Cell-responses after month 30 boost of gp120/MF59 delivered alone or with ALVAC-HIV (HIVR4P 2018, abstract PD03.05LB). AIDS Res Hum Retroviruses. 2018;34(S1):90.
   Google Scholar
• Barouch DH. A step forward for HIV vaccines. Lancet HIV. 2018;5(7):e338–e339.
   PubMed Web of Science ®Google Scholar
• Vaccari M, Gordon SN, Fourati S, et al. Adjuvant-dependent innate and adaptive immune signatures of risk of SIVmac251 acquisition. Nat Med. 2016;22(7):762–770.
   PubMed Web of Science ®Google Scholar
• Moody MA, Santra S, Vandergrift NA, et al. Toll-like receptor 7/8 (TLR7/8) and TLR9 agonists cooperate to enhance HIV-1 envelope antibody responses in rhesus macaques. J Virol. 2014;88(6):3329–3339.
   PubMed Web of Science ®Google Scholar
• Fouts TR, Bagley K, Prado IJ, et al. Balance of cellular and humoral immunity determines the level of protection by HIV vaccines in rhesus macaque models of HIV infection. Proc Natl Acad Sci U S A. 2015;112(9):E992–E999.
   PubMed Web of Science ®Google Scholar
• Beck Z, Matyas GR, Jalah R, et al. Differential immune responses to HIV-1 envelope protein induced by liposomal adjuvant formulations containing monophosphoryl lipid A with or without QS21. Vaccine. 2015;33(42):5578–5587.
   PubMed Web of Science ®Google Scholar
• Chea LS, Amara RR. Immunogenicity and efficacy of DNA/MVA HIV vaccines in rhesus macaque models. Expert Rev Vaccines. 2017;16(10):973–985.
   PubMed Web of Science ®Google Scholar
• Amara RR, Villinger F, Altman JD, et al. Control of a mucosal challenge and prevention of AIDS by a multiprotein DNA/MVA vaccine. Vaccine. 2002;20(15):1949–1955.
   PubMed Web of Science ®Google Scholar
• Hanke T, McMichael AJ, Mwau M, et al. Development of a DNA-MVA/HIVA vaccine for Kenya. Vaccine. 2002;20(15):1995–1998.
   PubMed Web of Science ®Google Scholar
• Hanke T, Goonetilleke N, McMichael AJ, et al. Clinical experience with plasmid DNA- and modified vaccinia virus Ankara-vectored human immunodeficiency virus type 1 clade A vaccine focusing on T-cell induction. J Gen Virol. 2007;88(Pt 1):1–12.
   PubMed Web of Science ®Google Scholar
• Kent S, De Rose R, Rollman E. Drug evaluation: DNA/MVA prime-boost HIV vaccine. Curr Opin Invest Drugs. 2007;8(2):159–167.
   PubMedGoogle Scholar
• Iyer SS, Amara RR. DNA/MVA vaccines for HIV/AIDS. Vaccines (Basel). 2014;2(1):160–178.
   PubMedGoogle Scholar
• Garcia-Arriaza J, Esteban M. Enhancing poxvirus vectors vaccine immunogenicity. Hum Vaccin Immunother. 2014;10(8):2235–2244.
   PubMed Web of Science ®Google Scholar
• Viegas EO, Tembe N, Nilsson C, et al. Intradermal HIV-1 DNA immunization using needle-free zetajet injection followed by HIV-modified vaccinia virus ankara vaccination is safe and immunogenic in mozambican young adults: a phase I randomized controlled trial. AIDS Res Hum Retroviruses. 2018;34(2):193–205.
   PubMed Web of Science ®Google Scholar
• Ake JA, Schuetz A, Pegu P, et al. Safety and immunogenicity of PENNVAX-G DNA prime administered by biojector 2000 or CELLECTRA electroporation device with modified vaccinia ankara-CMDR boost. J Infect Dis. 2017;216(9):1080–1090.
   PubMed Web of Science ®Google Scholar
• Hinkula J, Petkov S, Ljungberg K, et al. HIVIS-DNA or HIVISopt-DNA priming followed by CMDR vaccinia-based boosts induce both humoral and cellular murine immune responses to HIV. Heliyon. 2017;3(6):e00339.
   PubMed Web of Science ®Google Scholar
• Joachim A, Bauer A, Joseph S, et al. Boosting with subtype C CN54rgp140 protein adjuvanted with glucopyranosyl lipid adjuvant after priming with HIV-DNA and HIV-MVA is safe and enhances immune responses: a phase I trial. PLoS One. 2016;11(5):e0155702.
   PubMed Web of Science ®Google Scholar
• Nilsson C, Godoy-Ramirez K, Hejdeman B, et al. Broad and potent cellular and humoral immune responses after a second late HIV-modified vaccinia virus ankara vaccination in HIV-DNA-primed and HIV-modified vaccinia virus Ankara-boosted Swedish vaccinees. AIDS Res Hum Retroviruses. 2014;30(3):299–311.
   PubMed Web of Science ®Google Scholar
• Munseri PJ, Kroidl A, Nilsson C, et al. Priming with a simplified intradermal HIV-1 DNA vaccine regimen followed by boosting with recombinant HIV-1 MVA vaccine is safe and immunogenic: a phase IIa randomized clinical trial. PLoS One. 2015;10(4):e0119629.
   PubMed Web of Science ®Google Scholar
• Joachim A, Munseri PJ, Nilsson C, et al. Three-year durability of immune responses induced by HIV-DNA and HIV-modified vaccinia virus ankara and effect of a late HIV-modified vaccinia virus ankara boost in tanzanian volunteers. AIDS Res Hum Retroviruses. 2017;33(8):880–888.
   PubMed Web of Science ®Google Scholar
• Frahm N, Fiore-Gartland A, Malhi H, et al. Increased breadth of T-cell responses after mosaic HIV vaccination in humans (HVTN 106) (HIVR4P 2018, abstract OA07.01). AIDS Res Hum Retroviruses. 2018;34(S1):31.
   PubMedGoogle Scholar
• Goepfert P, Casapia M, Elizaga M, et al. HVTN114: a Phase 1 trial to evaluate late boosts with AIDSVAX B/E of participants previously vaccinated with MVA/HIV62B in DNA/MVA or MVA regimens (HIVR4P 2018, abstract P05.14LB). AIDS Res Hum Retroviruses. 2018;34(S1):184.
   Google Scholar
• Pissani F, Schulte B, Eller MA, et al. Modulation of vaccine-induced CD4 T cell functional profiles by changes in components of HIV vaccine regimens in humans. J Virol. 2018;92(23):e01143–e18.
   PubMed Web of Science ®Google Scholar
• Viegas EO, Kroidl A, Munseri PJ, et al. Optimizing the immunogenicity of HIV prime-boost DNA-MVA-rgp140/GLA vaccines in a phase II randomized factorial trial design. PLoS One. 2018;13(11):e0206838.
   PubMed Web of Science ®Google Scholar
• Excler JL, Rida W, Priddy F, et al. AIDS vaccines and preexposure prophylaxis: is synergy possible? AIDS Res Hum Retroviruses. 2011;27(6):669–680.
   PubMed Web of Science ®Google Scholar
• McNicholl JM. Combining biomedical preventions for HIV: vaccines with pre-exposure prophylaxis, microbicides or other HIV preventions. Hum Vaccin Immunother. 2016;12(12):3202–3211.
   PubMed Web of Science ®Google Scholar
• Harari A, Bart PA, Stohr W, et al. An HIV-1 clade C DNA prime, NYVAC boost vaccine regimen induces reliable, polyfunctional, and long-lasting T cell responses. J Exp Med. 2008;205(1):63–77.
   PubMed Web of Science ®Google Scholar
• Bart PA, Huang Y, Karuna ST, et al. HIV-specific humoral responses benefit from stronger prime in phase Ib clinical trial. J Clin Invest. 2014;124(11):4843–4856.
   PubMed Web of Science ®Google Scholar
• Garcia-Arriaza J, Perdiguero B, Heeney J, et al. Head-to-head comparison of poxvirus NYVAC and ALVAC vectors expressing identical HIV-1 clade C immunogens in prime-boost combination with env protein in nonhuman primates. J Virol. 2015;89(16):8525–8539.
   PubMed Web of Science ®Google Scholar
• Kibler KV, Asbach B, Perdiguero B, et al. Replication-competent NYVAC-KC yields improved immunogenicity to HIV-1 antigens in rhesus macaques, compared to non-replicating NYVAC. J Virol. 2019;93(3):e01513–e18.
   PubMed Web of Science ®Google Scholar
• Asbach B, Kibler KV, Kostler J, et al. Priming with a potent HIV-1 DNA vaccine frames the quality of immune responses prior to a poxvirus and protein boost. J Virol. 2019;93(3):e01529–e18.
   PubMed Web of Science ®Google Scholar
• Paris RM, Kim JH, Robb ML, et al. Prime-boost immunization with poxvirus or adenovirus vectors as a strategy to develop a protective vaccine for HIV-1. Expert Rev Vaccines. 2010;9(9):1055–1069.
   PubMed Web of Science ®Google Scholar
• Frahm N, DeCamp AC, Friedrich DP, et al. Human adenovirus-specific T cells modulate HIV-specific T cell responses to an Ad5-vectored HIV-1 vaccine. J Clin Invest. 2012;122(1):359–367.
   PubMed Web of Science ®Google Scholar
• Ondondo B, Abdul-Jawad S, Bridgeman A, et al. Characterization of T-cell responses to conserved regions of the HIV-1 proteome in BALB/c mice. Clin Vaccine Immunol. 2014;21(11):1565–1572.
   PubMed Web of Science ®Google Scholar
• Fausther-Bovendo H, Kobinger GP. Pre-existing immunity against Ad vectors: humoral, cellular, and innate response, what’s important? Hum Vaccin Immunother. 2014;10(10):2875–2884.
   PubMed Web of Science ®Google Scholar
• Barouch DH, Alter G, Broge T, et al. Protective efficacy of adenovirus/protein vaccines against SIV challenges in rhesus monkeys. Science. 2015;349(6245):320–324.
   PubMed Web of Science ®Google Scholar
• Barouch DH, Stephenson KE, Borducchi EN, et al. Protective efficacy of a global HIV-1 mosaic vaccine against heterologous SHIV challenges in rhesus monkeys. Cell. 2013;155(3):531–539.
   PubMed Web of Science ®Google Scholar
• Barouch DH, Liu J, Li H, et al. Vaccine protection against acquisition of neutralization-resistant SIV challenges in rhesus monkeys. Nature. 2012;482(7383):89–93.
   PubMed Web of Science ®Google Scholar
• Barouch DH, Tomaka FL, Wegmann F, et al. Evaluation of a mosaic HIV-1 vaccine in a multicentre, randomised, double-blind, placebo-controlled, phase 1/2a clinical trial (APPROACH) and in rhesus monkeys (NHP 13-19). Lancet. 2018;392(10143):232–243.
   PubMed Web of Science ®Google Scholar
• Stieh DJ, Callewaert K, Sarnecki M, et al. Primary analysis of TRAVERSE: a Phase 1/2a study to assess safety/tolerability and immunogenicity of 2 different prime/boost HIV vaccine regimens (HIVR4P 2018, abstract OA02.06LB). AIDS Res Hum Retroviruses. 2018;34(S1):18.
   Google Scholar
• Omosa-Manyonyi G, Mpendo J, Ruzagira E, et al. A Phase I double blind, placebo-controlled, randomized study of the safety and immunogenicity of an adjuvanted HIV-1 gag-pol-nef fusion protein and adenovirus 35 Gag-RT-int-nef vaccine in healthy HIV-uninfected African Adults. PLoS One. 2015;10(5):e0125954.
   PubMed Web of Science ®Google Scholar
• Ratto-Kim S, Currier JR, Cox JH, et al. Heterologous prime-boost regimens using rAd35 and rMVA vectors elicit stronger cellular immune responses to HIV proteins than homologous regimens. PLoS One. 2012;7(9):e45840.
   PubMed Web of Science ®Google Scholar
• Nyombayire J, Anzala O, Gazzard B, et al. First-in-human evaluation of the safety and immunogenicity of an intranasally administered replication-competent sendai virus-vectored HIV Type 1 gag vaccine: induction of potent T-cell or antibody responses in prime-boost regimens. J Infect Dis. 2017;215(1):95–104.
   PubMed Web of Science ®Google Scholar
• Crank MC, Wilson EM, Novik L, et al. Safety and Immunogenicity of a rAd35-EnvA prototype HIV-1 vaccine in combination with rAd5-EnvA in healthy adults (VRC 012). PLoS One. 2016;11(11):e0166393.
   PubMed Web of Science ®Google Scholar
• Walsh SR, Moodie Z, Fiore-Gartland AJ, et al. Vaccination with heterologous HIV-1 envelope sequences and heterologous adenovirus vectors increases T-cell responses to conserved regions: HVTN 083. J Infect Dis. 2016;213(4):541–550.
   PubMed Web of Science ®Google Scholar
• Parks CL, Picker LJ, King CR. Development of replication-competent viral vectors for HIV vaccine delivery. Curr Opin HIV AIDS. 2013;8(5):402–411.
   PubMed Web of Science ®Google Scholar
• Excler JL, Parks CL, Ackland J, et al. Replicating viral vectors as HIV vaccines: summary report from the IAVI-sponsored satellite symposium at the AIDS vaccine 2009 conference. Biologicals. 2010;38(4):511–521.
   PubMed Web of Science ®Google Scholar
• Stephenson KE, Keefer MC, Bunce CA, et al. First-in-human randomized controlled trial of an oral, replicating adenovirus 26 vector vaccine for HIV-1. PLoS One. 2018;13(11):e0205139.
   PubMed Web of Science ®Google Scholar
• Malherbe DC, Mendy J, Vang L, et al. Combination adenovirus and protein vaccines prevent infection or reduce viral burden after heterologous clade c simian-human immunodeficiency virus mucosal challenge. J Virol. 2018;92:2.
   Web of Science ®Google Scholar
• Buchbinder SP, Mehrotra DV, Duerr A, et al. Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the step study): a double-blind, randomised, placebo-controlled, test-of-concept trial. Lancet. 2008;372(9653):1881–1893.
   PubMed Web of Science ®Google Scholar
• Gray GE, Allen M, Moodie Z, et al. Safety and efficacy of the HVTN 503/Phambili study of a clade-B-based HIV-1 vaccine in South Africa: a double-blind, randomised, placebo-controlled test-of-concept phase 2b study. Lancet Infect Dis. 2011;11(7):507–515.
   PubMed Web of Science ®Google Scholar
• Hu H, Eller MA, Zafar S, et al. Preferential infection of human Ad5-specific CD4 T cells by HIV in Ad5 naturally exposed and recombinant Ad5-HIV vaccinated individuals. Proc Natl Acad Sci U S A. 2014;111(37):13439–13444.
   PubMed Web of Science ®Google Scholar
• Auclair S, Liu F, Niu Q, et al. Distinct susceptibility of HIV vaccine vector-induced CD4 T cells to HIV infection. PLoS Pathog. 2018;14(2):e1006888.
   PubMed Web of Science ®Google Scholar
• Churchyard GJ, Morgan C, Adams E, et al. A phase IIA randomized clinical trial of a multiclade HIV-1 DNA prime followed by a multiclade rAd5 HIV-1 vaccine boost in healthy adults (HVTN204). PLoS One. 2011;6(8):e21225.
   PubMed Web of Science ®Google Scholar
• Hammer SM, Sobieszczyk ME, Janes H, et al. Efficacy trial of a DNA/rAd5 HIV-1 preventive vaccine. N Engl J Med. 2013;369(22):2083–2092.
   PubMed Web of Science ®Google Scholar
• Enama ME, Ledgerwood JE, Novik L, et al. Phase I randomized clinical trial of VRC DNA and rAd5 HIV-1 vaccine delivery by intramuscular (i.m.), subcutaneous (s.c.) and intradermal (i.d.) administration (VRC 011). PLoS One. 2014;9(3):e91366.
   PubMed Web of Science ®Google Scholar
• Mpendo J, Mutua G, Nyombayire J, et al. A Phase I double blind, placebo-controlled, randomized study of the safety and immunogenicity of electroporated HIV DNA with or without interleukin 12 in prime-boost combinations with an Ad35 HIV vaccine in healthy HIV-seronegative African Adults. PLoS One. 2015;10(8):e0134287.
   PubMed Web of Science ®Google Scholar
• Clarke DK, Cooper D, Egan MA, et al. Recombinant vesicular stomatitis virus as an HIV-1 vaccine vector. Springer Semin Immunopathol. 2006;28(3):239–253.
   PubMed Web of Science ®Google Scholar
• Fauci AS, Marovich MA, Dieffenbach CW, et al. Immunology. Immune activation with HIV vaccines. Science. 2014;344(6179):49–51.
   PubMed Web of Science ®Google Scholar
• Fuchs JD, Frank I, Elizaga ML, et al. First-in-human evaluation of the safety and immunogenicity of a recombinant vesicular stomatitis virus human immunodeficiency Virus-1 gag vaccine (HVTN 090). Open Forum Infect Dis. 2015;2:3. ofv082
   PubMed Web of Science ®Google Scholar
• Elizaga ML, Li SS, Kochar NK, et al. Safety and tolerability of HIV-1 multiantigen pDNA vaccine given with IL-12 plasmid DNA via electroporation, boosted with a recombinant vesicular stomatitis virus HIV Gag vaccine in healthy volunteers in a randomized, controlled clinical trial. PLoS One. 2018;13(9):e0202753.
   PubMed Web of Science ®Google Scholar
• Li SS, Kochar NK, Elizaga M, et al. DNA priming increases frequency of T-cell responses to a vesicular stomatitis virus HIV vaccine with specific enhancement of CD8(+) T-cell responses by interleukin-12 plasmid DNA. Clin Vaccine Immunol. 2017;24(11):e00263–e17.
   PubMed Web of Science ®Google Scholar
• Pialoux G, Gahery-Segard H, Sermet S, et al. Lipopeptides induce cell-mediated anti-HIV immune responses in seronegative volunteers. AIDS. 2001;15(10):1239–1249.
   PubMed Web of Science ®Google Scholar
• Levy Y, Thiebaut R, Montes M, et al. Dendritic cell-based therapeutic vaccine elicits polyfunctional HIV-specific T-cell immunity associated with control of viral load. Eur J Immunol. 2014;44(9):2802–2810.
   PubMed Web of Science ®Google Scholar
• Frey SE, Peiperl L, McElrath MJ, et al. Phase I/II randomized trial of safety and immunogenicity of LIPO-5 alone, ALVAC-HIV (vCP1452) alone, and ALVAC-HIV (vCP1452) prime/LIPO-5 boost in healthy, HIV-1-uninfected adult participants. Clin Vaccine Immunol. 2014;21(11):1589–1599.
   PubMed Web of Science ®Google Scholar
• Dereuddre-Bosquet N, Baron ML, Contreras V, et al. HIV specific responses induced in nonhuman primates with ANRS HIV-Lipo-5 vaccine combined with rMVA-HIV prime or boost immunizations. Vaccine. 2015;33(20):2354–2359.
   PubMed Web of Science ®Google Scholar
• Malm M, Sikut R, Krohn K, et al. GTU-multihiv DNA vaccine results in protection in a novel P815 tumor challenge model. Vaccine. 2007;25(17):3293–3301.
   PubMed Web of Science ®Google Scholar